Essential Blood Tests: What to Check, How Often, and What Results Mean

An annual check-up can miss crucial markers. Five specific blood tests — backed by major cardiology and endocrinology guidelines — stand out as the most impactful for adults who want to stay ahead of preventable health issues like heart attack, diabetes, and kidney disease. This guide covers those five core tests, four additional panels worth considering for certain groups, and the evidence-based rationale behind each recommendation. It also addresses what to do if a result comes back abnormal, and whether newer blood tests — including multi-cancer early detection screens — are ready for routine use.

Lipoprotein(a) (Lp(a)) Test: The Overlooked Silent Risk

Starting with a test that is often overlooked by family doctors, yet is recommended by the European Atherosclerosis Society: Lipoprotein(a), or Lp(a).

Lipoproteins are the vehicles that carry cholesterol through the bloodstream. High levels of Lp(a) are a major risk factor for heart disease, aortic valve problems, and even death — and this risk does not discriminate by gender or ethnicity.

According to the American College of Cardiology, "Observational and genetic evidence strongly support the conclusion that high Lp(a) concentration is causal for ASCVD, aortic valve stenosis, and cardiovascular and all-cause mortality in men and women and across ethnic groups".

What makes Lp(a) particularly significant is that it is mostly determined by genetics. Unlike other lipoproteins, diet and exercise have little effect on Lp(a) levels. The same source emphasizes, "Lifestyle interventions have minimal impact on Lp(a)".

That is why the European Atherosclerosis Society recommends everyone get tested at least once in their adult life. The consensus statement is clear: "This panel recommends testing Lp(a) concentration at least once in adults".

If Lp(a) levels are elevated, it signals that other cardiovascular risk factors need more aggressive management — diet, exercise, blood pressure control, smoking cessation, and alcohol reduction. Think of it as reinforcing all the walls if one is already compromised. Managing stress also plays a role in overall cardiovascular risk reduction for those with elevated Lp(a).

The European Atherosclerosis Society considers an ideal Lp(a) level to be below 30 mg/dL or less than 75 nmol/L. Approximately 75% of adults fall below that threshold. For those above the ideal range, the clinical approach is to be more proactive in managing all other modifiable heart attack risk factors. Importantly, because Lp(a) is genetically determined and not meaningfully altered by lifestyle, knowing your level is a one-time test that informs lifetime risk awareness — not a measurement that needs frequent repeating.

Lipid or Cholesterol Panel: Understanding the Numbers

The second of the five lifesaving tests is a lipid or cholesterol panel. The key is accurate interpretation of the results.

A standard lipid panel measures total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides. There is considerable confusion online about blood cholesterol levels, so it is worth clarifying the fundamentals.

Cholesterol is essential for life — it contributes to cell membranes, hormones like testosterone, and bile acids needed for fat digestion. All cells in the body can produce their own cholesterol; as research confirms, cholesterol is "also synthesized by every cell in the body". The lipid panel is measuring only the cholesterol transported in the bloodstream, which represents a small fraction of the body's total cholesterol.

When there is too much LDL cholesterol in circulation, it can accumulate in artery walls — like debris piling up on a highway — eventually leading to the blockages that cause heart attacks and strokes.

Some sources suggest paying for additional tests like oxidized LDL or small dense LDL, arguing these are the real culprits. But the more precise framing focuses on the transport vehicles themselves — the lipoproteins. Those carrying an ApoB tag are the troublemakers, including all small, dense LDL particles. These particles can cross from the bloodstream into vessel walls; at high enough concentrations, they become trapped in the artery wall.

For those seeking a more precise measurement, an ApoB test provides direct quantification of these atherogenic particles — it counts every LDL, IDL, VLDL, and lipoprotein(a) particle, rather than estimating from cholesterol content. However, an ApoB test generally doubles the cost compared to a standard lipid panel, which is why most clinical guidelines continue to rely on LDL cholesterol measurement for routine screening. The two markers are strongly correlated in most people; ApoB becomes most clinically relevant when LDL and non-HDL results appear discordant.

The Evidence Behind Lowering LDL Cholesterol and ApoB

The evidence that lowering LDL cholesterol and ApoB reduces heart attacks is robust. Meta-analyses combining data from genetic studies and randomised controlled trials — covering over 20 million person-years of follow-up — conclusively establish that LDL causes heart disease. As one landmark study states: "Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD."

A common counterargument, particularly in online health discussions, is that insulin resistance, obesity, smoking, a sedentary lifestyle, and high blood pressure are the real drivers of heart disease — and that if those factors are addressed, blood cholesterol levels do not matter.

The PESA study directly addresses this claim. It found that even in individuals with optimal risk factors — no obesity, no smoking, no high blood pressure — arterial blockages still formed as LDL cholesterol levels rose. The study highlights: "Even in individuals with 'optimal' values for all CVRFs, there was a significant correlation between low-density lipoprotein cholesterol (LDL-C) concentration and the presence of atherosclerosis." It was only when LDL-C fell below 60 mg/dL that no vessel blockages were observed.

A 2024 study published in the Journal of the American College of Cardiology further demonstrates that for people without other heart risk factors, increasing LDL cholesterol and ApoB levels correlate with greater extent of arterial blockage.

The emerging view in the literature is that the optimal LDL-C level may be the level present at birth — approximately 20–40 mg/dL.

Concerns about lowering cholesterol too aggressively are addressed by the biology: since all cells manufacture their own cholesterol and blood levels represent only a fraction of total body cholesterol, studies show no concerning adverse effects even when LDL falls below 40 mg/dL. The brain, notably, synthesises its own cholesterol independently and does not rely on blood-borne supply.

Target ranges depend on individual risk profile, but broadly: for those who have already experienced a heart attack or stroke, the clinical goal is to reduce LDL as low as possible through a combination of dietary change, exercise, and cholesterol-lowering therapies — statins, ezetimibe, and PCSK9 inhibitors.

Statins: Addressing the Concerns

Statins are frequently mischaracterised in online health discussions, so it is worth reviewing the evidence on side effects directly.

Statins cause muscle aches in approximately 1–2% of people — and the risk is lower still with low-dose regimens, which deliver most of the cardiovascular benefit. Statins are not associated with cognitive impairment, and research does not support an effect on testosterone levels.

For adults without cardiovascular risk factors such as high blood pressure, diabetes, family history of heart disease, or smoking, clinical guidelines generally support a target LDL cholesterol below 70 mg/dL. For those with additional risk factors or a prior cardiovascular event, lower targets — below 55–60 mg/dL — are increasingly supported by the European Society of Cardiology and other major bodies. Low-dose rosuvastatin (5 mg) is one commonly used option for achieving lower LDL targets.

HbA1c Test: Monitoring Blood Sugar Levels

The third lifesaving test is HbA1c. This measurement reflects average blood sugar levels over the preceding 2–3 months — analogous to checking the prevailing weather pattern rather than today's temperature alone.

Online recommendations sometimes promote fasting insulin tests or continuous glucose monitors for non-diabetic individuals. As screening tools for primary care preventive medicine, however, those options do not change clinical management in the way HbA1c does.

If an HbA1c result indicates pre-diabetes, dietary changes become a priority: a pattern rich in non-starchy vegetables, legumes, nuts, whole fruits, and whole grains, with adequate lean protein from fish and poultry, while avoiding sugary, processed foods and fruit drinks.

Beyond diet, research suggests that metformin prescribed to pre-diabetic individuals can meaningfully reduce the risk of progressing to type 2 diabetes. Psyllium husk and GLP-1 receptor agonists (such as semaglutide) are additional options that clinical evidence supports in this context.

Kidney Function Tests: The Body's Filters

The fourth essential test covers kidney function — specifically sodium (Na), potassium (K), and creatinine. The kidneys are the body's filtration system, and these markers act like dashboard warning lights: they provide early signals if something is going wrong. Creatinine is used to calculate eGFR (estimated glomerular filtration rate), which indicates how efficiently the kidneys are filtering blood. Sodium and potassium imbalances can signal a range of conditions, from dehydration to adrenal issues to medication effects. Any abnormal result warrants prompt follow-up with a healthcare professional to determine the underlying cause.

Full Blood Count: The Early Warning System

The fifth core test is a full blood count (FBC). This panel assesses red blood cells, white blood cells, and platelets. Red blood cell indices can detect anaemia and help identify its type (iron-deficiency, B12-related, or other). The white blood cell differential can flag infections, immune conditions, or haematological concerns. Platelet counts inform bleeding risk and can be elevated in inflammatory states. Though basic, the FBC reliably surfaces issues that more targeted tests would miss — making it a genuinely valuable screening component. An abnormal result gives clinicians the cue to investigate further with more specific tests.

For the five core tests covered above, general guidance on screening frequency is as follows: adults aged 18–35, with normal initial results, can recheck every 2–3 years. Adults over 35 benefit from annual testing. These intervals assume no new symptoms or significant risk factor changes arise in between — if they do, earlier retesting is appropriate.

Why Not Test for Everything? The Role of Pretest Probability

If testing provides valuable information, why not screen for every condition, constantly?

The answer lies in test accuracy and pretest probability. No test is perfect — all carry false positive and false negative rates. Consider a test for a condition affecting 1 in 10,000 people, with a false positive rate of 1 in 1,000. For every 10 positive results, 9 would be incorrect. That creates anxiety and potential harm from unnecessary follow-up procedures, not genuine diagnostic value.

This is why clinicians focus on pretest probability — using medical history, demographics, and clinical presentation to identify which tests are most likely to yield actionable results for a given individual. Targeted testing reduces unnecessary worry and downstream harm from false positives.

Four Additional Blood Tests Certain Groups Should Consider

Beyond the five core tests, four additional panels are worth considering for specific groups:

Liver Function Tests
Liver function testing is indicated for individuals taking statins, those who drink alcohol regularly, those who are overweight, or those on other medications with hepatic effects. For otherwise healthy adults not on any medications, clinical guidelines do not recommend routine liver function screening — there is no demonstrated benefit in asymptomatic low-risk individuals.

Thyroid Function
Thyroid testing is recommended when there is a clinical reason — symptoms such as persistent fatigue, unexplained weight change, or hair thinning. For healthy adults with no symptoms, the guidelines do not support routine thyroid screening. Individuals can choose to test outside guidelines, but the evidence base for population-wide thyroid screening in asymptomatic people is not established.

Vitamins and Minerals
People with conditions that impair nutrient absorption — such as inflammatory bowel disease or coeliac disease — may benefit from targeted vitamin and mineral testing to ensure adequate status. For otherwise healthy adults following a balanced diet, routine micronutrient panels generally provide no additional clinical benefit.

PSA (Prostate-Specific Antigen)
PSA testing is available as a screening tool for prostate cancer in men. At present, it is the only blood-based cancer screening test with sufficient evidence for guideline endorsement. The Galleri multi-cancer early detection blood test is under active research, but the current evidence base does not yet support recommending it as a routine screening tool — it remains to be shown that it improves survival outcomes at a population level.

Conclusion: Focus on What Matters

Testing for everything might seem like a thorough approach, but it can generate more confusion than clarity. False positives lead to unnecessary investigations, anxiety, and sometimes procedures that carry their own risks. The most evidence-based strategy is to prioritise the tests that have been proven to make a difference — calibrated to individual risk factors, age, and health status.

The five core tests covered here — Lp(a), lipid panel, HbA1c, kidney function, and full blood count — represent the best current evidence for impactful preventive screening in adults. Together they capture the major modifiable drivers of premature death from cardiovascular disease, diabetes, and kidney failure. Acting on abnormal results early, when lifestyle and medical interventions are most effective, is where the real value of routine blood testing lies.

For the latest clinical guidance on vitamin D specifically — an area where guidelines have recently been updated — the Endocrine Society has released important new recommendations on who benefits most from testing and supplementation.

References

1. American College of Cardiology on Lp(a)
2. European Atherosclerosis Society on Lp(a)
3. Cholesterol Synthesis
4. ApoB Lipoproteins and Arterial Retention
5. LDL and Heart Disease Meta-Analysis
6. PESA Study
7. Optimal LDL-C Level at Birth
8. LDL-C Levels and Adverse Events Meta-Analysis
9. Brain Cholesterol Independence
10. European Society of Cardiology Guidelines on Lipid Control
11. Statin Muscle Pain Study
12. Statins and Cognitive Impairment
13. Statins and Testosterone